Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

Francesco Scaglione, Francesco Scaglione

Abstract

Botulinum neurotoxin has revolutionized the treatment of spasticity and is now administered worldwide. There are currently three leading botulinum neurotoxin type A products available in the Western Hemisphere: onabotulinum toxin-A (ONA) Botox(®), abobotulinum toxin-A (ABO), Dysport(®), and incobotulinum toxin A (INCO, Xeomin(®)). Although the efficacies are similar, there is an intense debate regarding the comparability of various preparations. Here we will address the clinical issues of potency and conversion ratios, as well as safety issues such as toxin spread and immunogenicity, to provide guidance for BoNT-A use in clinical practice. INCO was shown to be as effective as ONA with a comparable adverse event profile when a clinical conversion ratio of 1:1 was used. The available clinical and preclinical data suggest that a conversion ratio ABO:ONA of 3:1-or even lower-could be appropriate for treating spasticity, cervical dystonia, and blepharospasm or hemifacial spasm. A higher conversion ratio may lead to an overdosing of ABO. While uncommon, distant spread may occur; however, several factors other than the pharmaceutical preparation are thought to affect spread. Finally, whereas the three products have similar efficacy when properly dosed, ABO has a better cost-efficacy profile.

Keywords: abobotulinum toxin-A; botulinum neurotoxin; incobotulinum toxin A; onabotulinum toxin-A.

References

    1. Aoki K.R., Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions. Eur. J. Neurol. 2001;8(Suppl. 5):21–29. doi: 10.1046/j.1468-1331.2001.00035.x.
    1. Dressler D., Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil. Rehabil. 2007;29:1761–1768. doi: 10.1080/09638280701568296.
    1. Sesardic D., Leung T., Gaines-Das R. Role for standards in assays of botulinum toxins: International collaborative study of three preparations of botulinum type A toxin. Biologicals. 2003;31:265–276. doi: 10.1016/j.biologicals.2003.08.001.
    1. McLellan K., Das R.E., Ekong T.A., Sesardic D. Therapeutic botulinum type A toxin: Factors affecting potency. Toxicon. 1996;34:975–985. doi: 10.1016/0041-0101(96)00070-0.
    1. Chen J.J., Dashtipour K. Abo-, Inco-, Ona-, and Rima-Botulinum toxins in clinical therapy: A primer. Pharmacotherapy. 2013;33:304–318. doi: 10.1002/phar.1196.
    1. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R & D. 2015;15:1–9.
    1. Benecke R., Jost W.H., Kanovsky P., Ruzicka E., Comes G., Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64:1949–1951. doi: 10.1212/01.WNL.0000163767.99354.C3.
    1. Roggenkamper P., Jost W.H., Bihari K., Comes G., Grafe S., NT 201 blepharospasm study team Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J. Neural Transm. 2006;113:303–312.
    1. Jost W.H., Kohl A., Brinkmann S., Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J. Neural Transm. 2005;112:905–913. doi: 10.1007/s00702-004-0234-8.
    1. Park J., Lee M.S., Harrison A.R. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clin. Ophtalmol. 2011;5:725–732.
    1. Zoons E., Dijkgraaf M.G.W., Dijk J.M., van Schaik I.N., Tijssen M.A. Botulinum toxin as treatment for focal dystonia: A systematic review of the pharmaco-therapeutic and pharmaco-economic value. J. Neurol. 2012;259:2519–2526. doi: 10.1007/s00415-012-6510-x.
    1. Dressler D., Mander G., Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay. J. Neural Transm. 2012;119:13–15. doi: 10.1007/s00702-011-0719-1.
    1. Aoki K.R., Ranoux D., Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur. J. Neurol. 2006;13(Suppl. 4):10–19. doi: 10.1111/j.1468-1331.2006.01649.x.
    1. Wohlfarth K., Goschel H., Frevert J., Dengler R., Bigalke H. Botulinum A toxins: Units versus units. Arch. Pharmacol. 1997;355:335–340. doi: 10.1007/PL00004951.
    1. Marchetti A., Magar R., Findley L., Larsen J.P., Pirtosek Z., Ruzicka E., Jech R., Sławek J., Ahmed F. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Mov. Disord. 2005;20:937–944. doi: 10.1002/mds.20468.
    1. Marion M.H., Sheehy M., Sangla S., Soulayrol S. Dose standardisation of botulinum toxin. J. Neurol. Neurosurgery Psychiatry. 1995;59:102–103. doi: 10.1136/jnnp.59.1.102.
    1. Whurr R., Brookes G., Barnes C. Comparison of dosage effects between the American and British botulinum toxin A product in the treatment of spasmodic dysphonia. Mov. Disord. 1995;10 doi: 10.1002/mds.870100331.
    1. Kollewe K., Mohammadi B., Dengler R., Dressler D. Hemifacial spasm and reinnervation synkinesias: Long-term treatment with either Botox or Dysport. J. Neural Transm. 2010;177:759–763. doi: 10.1007/s00702-010-0409-4.
    1. Odergren T., Hjaltason H., Kaakkola S., Solders G., Hanko J., Fehling C., Marttila R.J., Lundh H., Gedin S., Westergren I., et al. A double-blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J. Neurol. Neurosurgery Psychiatry. 1998;64:6–12. doi: 10.1136/jnnp.64.1.6.
    1. Shin J.H., Jeon C., Woo K.I., Kim Y.D. Clinical comparability of Dysport and Botox in essential blepharospasm. J. Korean Ophthalmol. Soc. 2009;50:331–335. doi: 10.3341/jkos.2009.50.3.331.
    1. Wohlfarth K., Schwandt I., Wegner F., Jürgens T., Gelbrich G., Wagner A., Bogdahn U., Schulte-Mattler W. Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers: A double-blind, randomized, dose-ranging study. J. Neurol. 2008;255:1932–1939. doi: 10.1007/s00415-009-5182-7. Erratum in J. Neurol.2009, 256, 1201.
    1. Mohammadi B., Buhr N., Bigalke H., Krampfl K., Dengler R., Kollewe K. A long-term follow up of botulinum toxin A in cervical dystonia. Neurol. Res. 2009;31:463–466. doi: 10.1179/174313209X405137.
    1. Rystedt A., Nyholom D., Naver H. Clinical experience of dose conversion ratios between toxin products in the treatment of cervical dystonia. Clin. Neuropharmacol. 2012;35:278–282. doi: 10.1097/WNF.0b013e3182711fc0.
    1. Sampaio C., Ferreira J.J., Simões F., Rosas M.J., Magalhães M., Correia A.P., Bastos-Lima A., Martins R., Castro-Caldas A. Dysport: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox, assuming a ratio of 4:1. Mov. Disord. 1997;12:1013–1018. doi: 10.1002/mds.870120627.
    1. Nussgens Z. Comparison of two botulinum toxin preparations in the treatment of essential blepharospasm. Graefe′s Arch. Clin. Exp. Ophthalmol. 1997;235:197–199.
    1. Tidswell P., King M. Comparison of Two Botulinum Toxin Type-A Preparations in the Treatment of Dystonias. World Congress of Neurology; London, UK: 2001.
    1. Ranoux D., Gury C., Fondarai J., Mas J.L., Zuber M. Respective potencies of Botox and Dysport: A double-blind, randomised, crossover study in cervical dystonia. J. Neurol. Neurosurgery Psychiatry. 2002;72:459–462.
    1. Bentivoglio A.R., Ialongo T., Bove F., de Nigris F., Fasano A. Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: A novel paradigm for a never ending story. Neurol. Sci. 2012;33:261–267. doi: 10.1007/s10072-011-0672-7.
    1. Poewe W. Respective potencies of Botox and Dysport: A double blind, randomised, crossover study incervical dystonia. J. Neurol. Neurosurgery Psychiatry. 2002;72 doi: 10.1136/jnnp.72.4.430.
    1. Sampaio C., Costa J., Ferreira J.J. Clinical comparability of marketed formulations of botulinum toxin. Mov. Disord. 2004;19(Suppl. 19):S129–S136. doi: 10.1002/mds.20066.
    1. Van den Bergh P.Y.K., Lison D.F. Dose standardization of botulinum toxin. Adv. Neurol. 1998;78:231–235.
    1. Rosales R.L., Bigalke H., Dressler D. Pharmacology of botulinum toxin: Differences between type A preparations. Eur. J. Neurol. 2006;13(Suppl. 1):2–10. doi: 10.1111/j.1468-1331.2006.01438.x.
    1. Wohlfarth K., Sycha T., Ranoux D., Naver H., Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: Time for a reassessment? Curr. Med. Res. Opin. 2009;25:1573–1584. doi: 10.1185/03007990903028203.
    1. Keren-Capelovitch T., Jarus T., Fattal-Valevski A. Upper extremity function and occupational performance in children with spastic cerebral palsy following lower extremity botulinum toxin injections. J. Child Neurol. 2010;25:694–700. doi: 10.1177/0883073809344621.
    1. Brockmann K., Schweitzer K., Beck G., Wächter T. Comparison of different preparations of botulinumtoxinA in the treatment of cervical dystonia. Neurol. Asia. 2012;17:115–119.
    1. Kollewe K., Mohammadi B., Köhler S., Pickenbrock H., Dengler R., Dressler D. Blepharospasm: Long-term treatment with either Botox®, Xeomin® or Dysport®. J. Neural Transm. 2015;122:427–431. doi: 10.1007/s00702-014-1278-z.
    1. Rystedt A., Zetterberg L., Burman J., Nyholm D., Johansson A. A comparison of Botox 100 U/mL and Dysport 100 U/mL using dose conversion ratio 1:3 and 1:1.7 in the treatment of cervical dystonia: A double-Blind, randomized, crossover trial. Clin. Neuropharmacol. 2015;38:170–176. doi: 10.1097/WNF.0000000000000101.
    1. Yun J.Y., Kim J.W., Kim H.T., Chung S.J., Kim J.M., Cho J.W., Lee J.Y., Lee H.N., You S., Oh E., et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: A double-blind, randomized study. Mov. Disord. 2015;30:206–213. doi: 10.1002/mds.26085.
    1. Hambleton P., Pickett A.M. Potency equivalence of botulinum toxin preparations. J. R. Soc. Med. 1994;87:719.
    1. Highlights of prescribing information. [(accessed on 10 January 2016)]. Available online: .
    1. Dysport 300 units, Dysport 500 units—Summary of Product. [(accessed on 16 February 2016)]. Available online:
    1. Full prescribing information—Xeomin. [(accessed on 16 February 2016)]. Available online: .
    1. Wagman J., Bateman J.B. Botulinum type A toxin: Properties of toxic dissociation product. Arch. Biochem. Biophys. 1953;46:375–383. doi: 10.1016/S0003-9861(53)80014-7.
    1. Eisele K.H., Fink K., Vey M., Taylor H.V. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57:555–565. doi: 10.1016/j.toxicon.2010.12.019.
    1. Carli L., Montecucco C., Rossetto O. Assay of diffusion of different botulinum neurotoxin type A formulations injected in the mouse leg. Muscle Nerve. 2009;40:374–380. doi: 10.1002/mus.21343.
    1. Brodsky M.A., Swope D.M., Grimes D. Diffusion of botulinum toxins. [(accessed on 16 February 2016)];Tremor Other Hyperkinet. Mov. 2012 2:1346. Available online: .
    1. Roche N., Schnitzler A., Genet F.F., Durand M.C., Bensmail D. Undesirable distant effects following botulinum toxin type A injection. Clin. Neuropharmacol. 2008;31:272–280. doi: 10.1097/WNF.0b013e31815cba8a.
    1. Pickett A. Dysport: Pharmacological properties and factors that influence toxin action. Toxicon. 2009;54:683–689. doi: 10.1016/j.toxicon.2009.03.020.
    1. Kromminga A., Schellekens H. Antibodies against erythropoietin and other protein based therapeutics: An overview. Ann. N.Y. Acad. Sci. USA. 2005;1050:257–265. doi: 10.1196/annals.1313.027.
    1. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur. Neurol. 2002;48:26–29. doi: 10.1159/000064953.
    1. Bakheit A.M., Liptrot A., Newton R., Pickett A.M. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int. J. Rehabil. Res. 2012;35:36–39. doi: 10.1097/MRR.0b013e32834df64f.
    1. Benecke R. Clinical relevance of botulinum toxin immunogenicity. Biodrugs. 2012;26:e1–e9. doi: 10.2165/11599840-000000000-00000.
    1. Kukreja R., Chang T.-W., Cai S., Lindo P., Riding S., Zhou Y., Ravichandran E., Singh B.R. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon. 2009;53:616–624. doi: 10.1016/j.toxicon.2009.01.017.
    1. Atassi M.Z. On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin haemagglutinin. Microbiology. 2006;152:1891–1895. doi: 10.1099/mic.0.28862-0.
    1. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 2004;19(Suppl. 8):S68–S84. doi: 10.1002/mds.20020.
    1. Bigalke H. Properties of pharmaceutical products of botulinum neurotoxins. In: Jankovic J., Albanese A., Atassi M.Z., Dolly J.O., Hallett M., Mayer N.H., editors. Botulinum Toxin: Therapeutic Clinical Practice and Science. Saunders Elsevier; Philadelphia, PA, USA: 2009. pp. 389–397.
    1. Frevert J. Content of botulinum neurotoxin in Botox/Vistabel, Dysport/Azzalure, and Xeomin/Bocouture. Drugs R & D. 2010;10:67–73.
    1. Jankovic J., Esquenazi A., Fehlings D., Freitag F., Lang A., Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin. Neuropharmacol. 2004;27:234–244. doi: 10.1097/01.wnf.0000145508.84389.87.
    1. Lundström E., Smits A., Borg J., Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: The first year after the event. Stroke. 2010;41:319–324. doi: 10.1161/STROKEAHA.109.558619.
    1. Francis H.P., Wade D.T., Turner-Stokes L., Kingswell R.S., Dott C.S., Coxon E.A. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J. Neurol. Neurosurgery Psychiatry. 2004;75:1547–1551. doi: 10.1136/jnnp.2003.025551.
    1. Lukban M.B., Rosales R.L., Dressler D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: A summary of evidence. J. Neural Transm. 2009;116:319–331. doi: 10.1007/s00702-008-0175-8.
    1. Ward A., Roberts G., Warner J., Gillard S. Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J. Rehabil. Med. 2005;37:252–257. doi: 10.1080/16501970510027312.
    1. Shaw L., Rodgers H., Price C., van Wijck F., Shackley P., Steen N., Barnes M., Ford G., Graham L., BoTULS Investigators BoTULS: A multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol. Assess. 2010;14:1–113. doi: 10.3310/hta14260.
    1. Doan Q.V., Gillard P., Brashear A., Halperin M., Hayward E., Varon S., Lu Z.J. Cost-effectiveness of onabotulinumtoxin A for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. Eur. J. Neurol. 2013;20:773–780. doi: 10.1111/ene.12062.
    1. Roze S., Kurth H., Hunt B., Valentine W., Marty R. Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: Comparison of two preparations in 19 countries. Med. Devices. 2012;5:97–101.
    1. Abogunrin S., Brand S., Desai K., Dinet J., Gabriel S., Harrower T. Abobotulinumtoxin A in the management of cervical dystonia in the United Kingdom: A budget impact analysis. Clin. Econ. Outcomes Res. 2015;7:441–449. doi: 10.2147/CEOR.S86355.
    1. Kazerooni R., Broadhead C. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia. Am. J. Health Syst. Pharm. 2015;72:301–307. doi: 10.2146/ajhp140276.
    1. Grosset D.G., Tyrrell E.G., Grosset K.A. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: A review of 257 cases. J. Rehabil. Med. 2015;47:183–186. doi: 10.2340/16501977-1895.
    1. Tilden D., Guarnieri C., Jackson D. Cost-effectiveness of incobotulinumtoxin-A with flexible treatment intervals compared to onabotulinumtoxin-A in the management of blepharospasm and cervical dystonia. Value Health. 2015;18:A759. doi: 10.1016/j.jval.2015.09.2475.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe